DXR

Daxor Corporation · NASDAQ · Healthcare · USD · 10-K for 2011, filed 2012-03-28

Figures on this page computed 2026-11-08 12:58 UTC

Last close

8.91USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2011, filed 2012-03-28

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2011
Accession
0001019056-12-000401
Reported in
USD
- computed
- 10-K for 2011, filed 2012-03-28
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2011
Accession
0001019056-12-000401
Reported in
USD
- 10-K for 2011, filed 2012-03-28
- 10-K for 2011, filed 2012-03-28
- 10-K for 2011, filed 2012-03-28
- 10-K for 2011, filed 2012-03-28
- 10-K for 2011, filed 2012-03-28
- 10-K for 2011, filed 2012-03-28
The filing itself
-496.8%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2011
Accession
0001019056-12-000401
Reported in
USD
- 10-K for 2011, filed 2012-03-28
- 10-K for 2011, filed 2012-03-28
The filing itself
-458.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2011
Accession
0001019056-12-000401
Reported in
USD
- 10-K for 2011, filed 2012-03-28
- 10-K for 2011, filed 2012-03-28
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2011
Accession
0001019056-12-000401
Reported in
USD
- 10-K for 2011, filed 2012-03-28
- 10-K for 2011, filed 2012-03-28
The filing itself
n/aDividend yield
The stored value is a zero that stands for missing data rather than a measurement, so we will not place it.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
- Computed from the filing for 2010

What it pays out is the furthest below its sector's middle: 0.04 against 0.50 on the market's range.

Against its rival

lens 4 of 9

Measure by measure

behind on 2 of 3

Profit on each unit of sales-497%-65.5%Behind
Higher is better here.
Return on the capital it usesn/a-97.2%n/a
Higher is better here.
Sales growth over five years-0.6%-3.3%Ahead
Higher is better here.
Debt against equityn/a3.22n/a
Lower is better here.
Gross margin54.9%57.7%Behind
Higher is better here.
Price against earningsn/an/an/a
Lower is better here.

The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.

Against Harvard Bioscience, Inc., DXR is behind on 2 of 3 measures.

Every figure in this lens

Except where said otherwise: 10-K for 2011, filed 2012-03-28

Profit on each unit of sales-496.8%
Source
filed
Statement
income
Fiscal year
2011
Accession
0001019056-12-000401
Reported in
USD
The filing itself
Return on the capital it usesn/a
Not held.
Source
filed
Statement
income
Fiscal year
2011
Accession
0001019056-12-000401
Reported in
USD
The filing itself
Sales growth over five years-0.6%
Source
filed
Statement
income
Fiscal year
2011
Accession
0001019056-12-000401
Reported in
USD
The filing itself
Debt against equityn/a
Not held.
Source
filed
Statement
income
Fiscal year
2011
Accession
0001019056-12-000401
Reported in
USD
The filing itself
Gross margin54.9%
Source
filed
Statement
income
Fiscal year
2011
Accession
0001019056-12-000401
Reported in
USD
The filing itself
Price against earningsn/a
Not held.
Source
filed
Statement
income
Fiscal year
2011
Accession
0001019056-12-000401
Reported in
USD
The filing itself